Diversified Trust Co Sells 15,312 Shares of Johnson & Johnson (NYSE:JNJ)

Diversified Trust Co trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 14.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 89,528 shares of the company’s stock after selling 15,312 shares during the quarter. Diversified Trust Co’s holdings in Johnson & Johnson were worth $12,948,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Canandaigua National Trust Co of Florida lifted its holdings in shares of Johnson & Johnson by 13.2% in the fourth quarter. Canandaigua National Trust Co of Florida now owns 2,250 shares of the company’s stock valued at $325,000 after purchasing an additional 263 shares in the last quarter. Capital Market Strategies LLC lifted its stake in Johnson & Johnson by 5.8% in the 4th quarter. Capital Market Strategies LLC now owns 7,723 shares of the company’s stock valued at $1,117,000 after acquiring an additional 425 shares in the last quarter. Pensionfund Sabic grew its stake in shares of Johnson & Johnson by 49.2% during the 4th quarter. Pensionfund Sabic now owns 27,300 shares of the company’s stock worth $3,948,000 after acquiring an additional 9,000 shares in the last quarter. Nordea Investment Management AB raised its holdings in shares of Johnson & Johnson by 13.7% in the fourth quarter. Nordea Investment Management AB now owns 6,424,675 shares of the company’s stock valued at $926,438,000 after purchasing an additional 775,490 shares during the last quarter. Finally, Versant Capital Management Inc lifted its position in shares of Johnson & Johnson by 27.8% in the fourth quarter. Versant Capital Management Inc now owns 4,678 shares of the company’s stock worth $677,000 after purchasing an additional 1,019 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In related news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of JNJ traded up $2.53 during mid-day trading on Tuesday, hitting $146.19. 2,360,804 shares of the company’s stock were exchanged, compared to its average volume of 5,477,810. The stock’s 50-day simple moving average is $151.03 and its 200-day simple moving average is $156.25. Johnson & Johnson has a 52 week low of $142.75 and a 52 week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a market cap of $351.97 billion, a price-to-earnings ratio of 21.16, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter in the prior year, the business posted $2.66 earnings per share. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.39%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Royal Bank of Canada boosted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley upped their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Citigroup decreased their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, Bank of America reissued a “neutral” rating and set a $166.00 price target on shares of Johnson & Johnson in a research report on Tuesday, December 10th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $174.71.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.